A naukri.com initiative
Bioengineer
7d
0
Image Credit: Bioengineer
Tumor-Microenvironment Crosstalk Drives NSCLC Progression, Therapy Response
- Non-small-cell lung cancer (NSCLC) treatment landscape is evolving rapidly with targeted therapies and immunotherapeutic approaches, but some patients still experience limited responses.
- Research emphasizes the crucial role of the tumor microenvironment (TME) in driving NSCLC progression, metastasis, and therapeutic resistance.
- TME comprises diverse cellular and non-cellular components, influencing cancer behavior and treatment outcomes through intricate cross-talk with tumor cells.
- Spatial niches within the TME exhibit distinct features like immune-infiltrated zones and immune-excluded regions, affecting therapy responses differently.
- Inflammation and immunosuppression balance plays a key role in NSCLC progression, with TME shifts promoting immune evasion post-tumor establishment.
- Patient-specific factors such as aging, sex, and socioeconomic status influence NSCLC-TME interactions, requiring personalized therapeutic considerations.
- Therapeutic strategies for NSCLC now focus on integrating immune modulation and TME remodeling to overcome resistance mechanisms and enhance treatment efficacy.
- Targeting the extracellular matrix (ECM) and cancer-associated fibroblasts (CAFs) within the TME presents promising avenues to improve drug delivery and immune responses.
- Understanding pre-metastatic niches and secondary microenvironments is crucial in limiting metastatic progression and developing targeted interventions.
- Therapeutic resistance in NSCLC arises from diverse mechanisms involving both tumor cell adaptations and TME-mediated influences, necessitating dynamic treatment approaches.
Read Full Article
Like
For uninterrupted reading, download the app